Home → E-shop → Nucleotides → Trifluridine triphosphate – CAS 345-03-9

Trifluridine triphosphate – CAS 345-03-9

Trifluridine triphosphate – CAS 345-03-9 is synthesised by Sigut Labs (Prague, Czech Republic).

Purity (LC-MS)

99%+

Package contents

Trifluridine triphosphate Et₃NH⁺salt

This compound is for research use only. We do not sell to patients.

Amount

1 mg	€ 800	Stock
5 mg	€ 3500	Stock
10 mg	€ 6500	Stock
100mM/10μL	€ 800	Stock
10mM/100μL	€ 800	Stock
Do you want custom amount?			Custom amount

Amount

1 mg

€ 800

Stock

5 mg

€ 3500

Stock

View more amounts

Characterisation

CAS: 345-03-9, 2736455-55-1 (Et3NH+ salt)

IUPAC name: [[(2R,3S,5R)-5-[2,4-dioxo-5-(trifluoromethyl)pyrimidin-1-yl]-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate

Other names: Trifluridine triphosphate, Trifluridine TP

Molecular weight: 536.15 g/mol

Molecular formula: C₁₀H₁₄F₃N₂O₁₄P₃

InChI: InChI=1S/C10H14F3N2O14P3/c11-10(12,13)4-2-15(9(18)14-8(4)17)7-1-5(16)6(27-7)3-26-31(22,23)29-32(24,25)28-30(19,20)21/h2,5-7,16H,1,3H2,(H,22,23)(H,24,25)(H,14,17,18)(H2,19,20,21)/t5-,6+,7+/m0/s1

Description

Trifluridine (also called trifluorothymidine; abbreviation TFT or FTD) is an anti-herpesvirus antiviral drug, used primarily on the eye. It was sold under the trade name Viroptic by Glaxo Wellcome, now merged into GlaxoSmithKline. The brand is now owned by Monarch Pharmaceuticals, which is wholly owned by King Pharmaceuticals.

Trifluridine was approved for medical use in 1980. It is also a component of the anti-cancer drug trifluridine/tipiracil, which is taken by mouth.

You can read about other antiviral drugs synthesised at Sigut Labs in our article.

Chemicals are distributed worldwide

Buy Trifluridine triphosphate now, and get your order in 48 hours

Shipping through DHL in 48 hours
Sensitive compounds are shipped on dry ice
All compounds are safely and rigorously packed

Payment

Payment terms 30 days net
We are sending the invoice the same day as the shipment
We are able to modify the invoice for the academic institution, so the order can be paid from grants

References

Herold, N., Rudd, S. G., Sanjiv, K., Kutzner, J., Bladh, J., Paulin, C. B., … & Schaller, T. (2017). SAMHD1 protects cancer cells from various nucleoside-based antimetabolites. Cell Cycle, 16(11), 1029-1038.
Burness, C. B., & Duggan, S. T. (2016). Trifluridine/tipiracil: a review in metastatic colorectal cancer. Drugs, 76, 1393-1402.
Kaufman, H. E., Varnell, E. D., & Thompson, H. W. (1998). Trifluridine, cidofovir, and penciclovir in the treatment of experimental herpetic keratitis. Archives of ophthalmology, 116(6), 777-780.
Brady, R. C., & Bernstein, D. I. (2004). Treatment of herpes simplex virus infections. Antiviral research, 61(2), 73-81.